A documentalist is a professional, trained in documentation science and specializing in assisting researchers in their search for scientific and technical documentation. With the development of bibliographical databases such as MEDLINE, documentalists were professionals who searched such databases on the behalf of users. When the field of documentation changed its name to information science, the terms information specialist or information professional often replaced the term documentalist.
List of security-focused operating systems
This is a list of operating systems specifically focused on security. Similar concepts include security-evaluated operating systems that have achieved certification from an auditing organization, and trusted operating systems that provide sufficient support for multilevel security and evidence of correctness to meet a particular set of requirements. == Linux == === Android-based === GrapheneOS is a security-focused, Android-based mobile OS that uses a hardened kernel, C library, custom memory allocator (hardened_malloc), and a hardened Chromium-based browser named Vanadium. It also offers privacy/security features, such as Duress PIN/Password or disabling the USB-C port at a driver/hardware level to avoid exploitation. It deploys exploit mitigations such as hardware-based memory tagging, secure app spawning, restricted dynamic code loading, and more. === Debian-based === Linux Kodachi is a security-focused operating system. Tails is aimed at preserving privacy and anonymity. KickSecure is a security-focused Linux distribution that aims to be "hardened by default". It uses network hardening, kernel hardening, Strong Linux User Account Isolation, better randomness, root access restrictions, and app-specific hardening. Whonix is an anonymity focused operating system based on KickSecure. It consists of two virtual machines, And all communications are routed through Tor. === Other Linux distributions === Alpine Linux is designed to be small, simple, and secure. It uses musl, BusyBox, and OpenRC instead of the more commonly used glibc, GNU Core Utilities, and systemd. Owl - Openwall GNU/Linux, a security-enhanced Linux distribution for servers. Secureblue, a Fedora Silverblue based distro that uses a hardened kernel, custom memory allocator (hardened_malloc), Trivalent, a security-focused, Chromium-based browser inspired by Vanadium, and many other exploit mitigations. == BSD == OpenBSD is a Unix-like operating system that emphasizes portability, standardization, correctness, proactive security, and integrated cryptography. == Xen == Qubes OS aims to provide security through isolation. Isolation is provided through the use of virtualization technology. This allows the segmentation of applications into secure virtual machines.
ACM SIGEVO
The ACM SIGEVO is a Special Interest Group of the Association of Computing Machinery for members of that organization who are practitioners, academics, students or others with interests in evolutionary computation and related algorithms. == History == ACM SIGEVO was founded in 2005 when the International Society for Genetic and Evolutionary Computation (ISGEC) became an ACM Special Interest Group under its present title. The ISGEC had been formed in 1999 by the merger of the Genetic Programming conference organization with the International Conference on Genetic Algorithms (ICGA) leading to the first Genetic and Evolutionary Computation Conference (GECCO). == Membership == Members of this SIG pay a small fee in addition to the ACM membership fee. In return they have access to a quarterly online newsletter, but more importantly can obtain reduced registration rates at the two conferences organised by ACM SIGEVO: GECCO and the Foundations of Genetic Algorithms conference (FOGA). They can also access material on evolutionary computation and related topics in the ACM Digital Library. In addition they can subscribe to email mailing lists in order to keep informed about news over time. For students, ACM SIGEVO sponsors Travel Awards for attendance at the GECCO Conference and FOGA (the Foundations of Genetic Algorithms conference). ACM SIGEVO also sponsors a Graduate Student Workshop. ACM also sponsors Awards to be competed for by attendees at the conferences it organises. == Conferences == ACM SIGEVO organises two major conferences in the field of evolutionary computation. The Genetic and Evolutionary Conference (GECCO) is held annually, while the Foundations of Genetic Algorithms conference (FOGA) is held biennially. === GECCO === The first GECCO conference was held prior to the formation of ACM SIGEVO but since 2005 (see History above) it has been organised annually by ACM SIGEVO. The latest (2025) was held in Málaga, Spain. The next (2026) will be held in San José, Costa Rica. === FOGA === Foundations of Genetic Algorithms (FOGA) is a biennial peer-reviewed research conference focusing on the theoretical principles underlying genetic algorithms, other evolutionary algorithms and related heuristics. It is organized by ACM SIGEVO. Its relevance to the computer science research community has been reflected in an A-rating in the CORE computer science conference assessment system. The Foundations of Genetic Algorithms (FOGA) conference originated as a workshop in 1990 in order to create an opportunity for researchers on genetic algorithms and related areas of evolutionary computation to focus on the theoretical principles underlying their field. From the start its multi-day duration made it comparable to conferences in the field, and since 2015 its proceedings have used conference rather than workshop in their titles. In 2005 ACM SIGEVO the Association for Computing Machinery Special Interest Group on Genetic and Evolutionary Computation was formed and every FOGA conference since then has been supported by SIGEVO. The table below shows FOGA conferences by year, location, websites (where available) and publisher of proceedings. A citation follows the reference to the publisher giving the full details of each FOGA proceedings. Papers accepted at recent conferences have been presented as digital or print posters in poster sessions at the conference, before being published in written form in the conference proceedings. FOGA is comparable in its multi-day duration to other conferences on evolutionary computation such as CEC, GECCO and PPSN. The main difference is that FOGA focuses on the theoretical basis of evolutionary computation and related subjects. While the above conferences devote some time to theory they also cover a wide range of other topics including competitions and applications. This focus on theoretical computer science was reflected in the CORE computer science conference assessment exercise, where FOGA was given an A-ranking in the 2023 assessment. GECCO and PPSN also obtained A-rankings, but many other conferences in the field of evolutionary computation obtained lower rankings. This suggests that FOGA is a relevant conference in its field, comparable with others including the much larger CEC or GECCO. Keynote speakers at past conferences have been: == Awards == ACM SIGEVO sponsors a number of awards. === SIGEVO Outstanding Contribution Award === The SIGEVO Outstanding Contribution Award commenced in 2023, and these awards are designed to recognise distinctive contributions to the field of evolutionary computation when evaluated over a period of at least 15 years. As a result many recipients to date are notable academics or industrial practitioners, and include Anne Auger, Kalyanmoy Deb, Stephanie Forrest, Emma Hart and Hans-Paul Schwefel. === SIGEVO Dissertation Award === The SIGEVO Dissertation Award recognises thesis research in the field of evolutionary computation completed at least by the year prior to a GECCO conference. Theses are submitted and reviewed by a panel that selects one winner and a maximum of two honourable mentions. Awards will be made to the winner and any others at the next GECCO conference. === SIGEVO Chair Award === The SIGEVO Chair Award, established in 2016 is a lecture sponsored by ACM SIGEVO, to take place on the last day of the GECCO conference. It recognizes through the lectures that the lecturers are influential researchers in the field of evolutionary computation. The more recent lectures are available online. The 2024 Award winner was Una-May O'Reilly. === SIGEVO Impact Award === The SIGEVO Impact Award looks back to the GECCO conference ten years earlier and recognizes up to three papers a year which are considered by the current ACM SIGEVO Executive Committee to have had significant impact over the period since their first publication at the GECCO conference. An example (originally published in GECCO 2010) received this award in 2020. === GECCO Best Paper Award === The ACM SIGEVO sponsors awards for the best papers presented at the GECCO conference. Because GECCO conferences have very many parallel tracks there are multiple awards recognising presentations in the different tracks. At GECCO 2025 Best Paper Awards were presented across 12 tracks. === FOGA Best Paper Award === The ACM SIGEVO sponsors awards for the best papers presented at the FOGA conference. Because FOGA operates on a single track, it is easier to compare papers. Since 2019 this Award has been made (suggesting only four awards up to the latest conference in 2025). ACM SIGEVO records the 2019 award. === Humie Award === The Humies Awards are rewards for the best form of human-competitive results using evolutionary computation or related algorithms and published in the wider literature (they do not need to be published at a conference or in a journal sponsored by ACM SIGEVO or even the ACM.) They were established through a gift from John Koza and have been in operation from 2004 to the present. The link with ACM SIGEVO is that the winners of the competition (submissions are evaluated in advance) are presented with Humie Awards at GECCO conferences. The Humie Awards website provides full details for the rules and how to submit entries to the competition. == Journals == ACM SIGEVO sponsors the main journal covering evolutionary computation published by the ACM: ACM Transactions on Evolutionary Learning and Optimization. ACM SIGEVO refers to the preceding ISGEC organisation (see History above) as sponsoring two other important journals in the field: The Evolutionary Computation journal. Genetic Programming and Evolvable Machines. While these journals continue to be important in the field, the wording on the website of ACM SIGEVO suggests that ACM SIGEVO is not involved in their publication. == References and notes ==
Artificial intelligence in pharmacy
Artificial intelligence in pharmacy refers to the application of artificial intelligence (AI) techniques across pharmaceutical research and practice, including drug discovery, drug delivery, safety monitoring, clinical decision support, and pharmacy operations. Machine learning, deep learning, and natural language processing have been applied to tasks ranging from molecular design to patient adherence monitoring, with the aim of reducing development costs, improving accuracy, and personalizing treatment. Adoption has been uneven. Barriers include limited AI training among pharmacists, high infrastructure costs, and the risk of harm from models trained on unrepresentative data. Regulatory frameworks for AI-based pharmaceutical tools remain in active development across most jurisdictions. == Applications == === Drug discovery and development === Drug development is resource-intensive: bringing a single drug to market typically costs around $2.6 billion and takes 12–14 years. Machine learning algorithms have been applied to analyze molecular datasets to identify potential drug candidates, predict drug–target interactions, and optimize formulations. Artificial neural networks and generative adversarial networks have been used in drug discovery tasks including virtual screening, structure-activity relationship modeling, and de novo molecule generation. Peptides designed using AI methods have shown activity against multidrug-resistant bacteria, and transcriptomic data from human cell lines has been used to train deep learning models to classify drugs by therapeutic properties. Results in drug discovery have been mixed. AI models depend on the quality and diversity of their training data; those trained on narrow chemical libraries can fail to generalize to novel molecular scaffolds. The gap between high virtual screening hit rates and success in preclinical or clinical testing remains a persistent challenge, and the translation of computationally predicted candidates into approved drugs has been slower than early projections suggested. === Drug delivery systems === AI methods including neural networks, principal component analysis, and neuro-fuzzy logic have been applied to identifying biological targets for pharmaceuticals and analyzing genetic information relevant to drug design. Computational models can predict how a formulation will behave in biological systems, helping narrow the field before laboratory synthesis begins. Systems have been proposed that monitor patient response and adjust doses in real time based on individual physiology, with potential applications in chronic disease management. Research has also explored AI applications in targeted cancer treatments and oral vaccine delivery, areas where precise control over drug release kinetics is a design priority. === Drug safety === AI has been applied to predicting and detecting adverse drug reactions using techniques including knowledge graphs, logistic regression classifiers, and neural networks. A 2023 study developed a machine learning algorithm using knowledge graph analysis to classify known causes of adverse reactions. Natural language processing and deep learning models including long short-term memory (LSTM) networks have shown better performance than conventional methods for detecting opioid misuse, drawing on both structured data from electronic health records and unstructured sources such as clinical notes. AI-based pharmacovigilance systems can scan large volumes of electronic health records and social media for drug safety signals at a scale not feasible with manual review. Limitations include difficulty distinguishing drug-related adverse events from unrelated conditions in free-text data, and the need for validated benchmarks to measure model performance against existing safety monitoring standards. === Clinical decision support and personalized medicine === Machine learning systems trained on patient datasets can predict individual risk profiles, including potential allergies and drug–drug interactions, reducing the risk of harm in complex polypharmacy cases where the number of possible interactions exceeds what a clinician can readily assess. Personalized dosing models have been developed for drugs with narrow therapeutic windows — including anticoagulants and immunosuppressants — using patient-specific variables such as weight, renal function, and relevant genetic markers. Prospective clinical validation of these systems has lagged behind their technical development. Most published evaluations report performance on retrospective datasets, and the regulatory pathway for AI-based clinical decision support tools in pharmacy varies by jurisdiction. === Pharmacy operations and automation === Robotic and AI-driven systems have been applied to dispensing accuracy and pharmacy logistics. At the UCSF Medical Center, robotic technology produced 350,000 medication doses with no dispensing errors recorded. Robots such as TUG assist with preparing and transporting medications and laboratory samples within hospital settings. AI has also been applied to inventory management, with demand-forecasting systems predicting medicine requirements to reduce shortages and minimize waste from expired stock. In community pharmacy settings, AI tools have been used to flag potential prescription errors and alert pharmacists to drug–drug interactions before dispensing. === Medication adherence === Confirming that patients take prescribed medications as directed is a persistent challenge in healthcare. AI-enabled tools including smart pillboxes, RFID tags, ingestible sensors, and video check-ins have been applied to this problem. Smart pillboxes record when they are opened, providing real-time adherence data that can be reviewed remotely by care teams. Ingestible sensors transmit a signal after dissolution, offering direct confirmation of ingestion rather than proxy measures such as pill count or self-report. == Adoption challenges == === Barriers === Several barriers limit AI adoption in pharmacy practice. Many published evaluations report model performance on retrospective datasets rather than prospective clinical outcomes, making it difficult to assess real-world benefit. Pharmacists have reported limited AI training and knowledge, and research facilities often lack the computational infrastructure required for model development and validation. Models trained on biased or unrepresentative datasets can produce misleading results with direct patient safety consequences. === Regulatory frameworks === Regulatory frameworks for AI-based pharmaceutical tools are in active development. In the United States, the Food and Drug Administration (FDA) has issued guidance on AI and machine learning-based software as a medical device, addressing requirements for pre-market review and post-market performance monitoring. The European Medicines Agency has published discussion papers on the use of AI across the medicines development lifecycle, with particular attention to transparency in model training and validation. The absence of harmonized international standards creates compliance complexity for developers operating across multiple jurisdictions. === Ethical challenges === AI adoption raises data privacy and security concerns, including the risk of exposing sensitive patient information through data breaches. Algorithmic bias presents a related hazard: a model trained on an unrepresentative patient population may generate unsuitable treatment recommendations for patients not reflected in its training data, with potential for disparate outcomes across demographic groups. The opacity of some machine learning models, particularly deep neural networks, limits clinicians' ability to interpret or contest a recommendation, raising questions of accountability when a model-assisted decision results in patient harm. === Proposed solutions === Responses proposed in the literature include AI-focused education programs for pharmacists, increased public funding for healthcare AI research, encryption and governance frameworks for patient data, and regulatory requirements to prevent the use of biased training datasets. Greater transparency about training data provenance, model architecture, and validation methodology has also been recommended, including disclosure requirements in regulatory submissions. === Future directions === Research groups have called for tighter integration between AI systems and electronic health records to reduce healthcare costs and improve continuity of care across settings. International collaboration through shared AI frameworks and federated learning approaches has been proposed to address data scarcity in underrepresented patient populations and accelerate validation across institutions.
European Society for Fuzzy Logic and Technology
The European Society for Fuzzy Logic and Technology (EUSFLAT) is a scientific association with the aims to disseminate and promote fuzzy logic and related subjects (sometimes comprised under the collective terms soft computing or computational intelligence) and to provide a platform for exchange between scientists and engineers working in these fields. The society is both open for academic and industrial members. == History == EUSFLAT was founded in 1998 in Spain as the successor of the National Spanish Fuzzy Logic Society, ESTYLF, with the aim to open the society for members from other European countries. Since then, the society managed to attract a large share of members from outside Spain, and even beyond Europe, with the Spanish members still being the largest group inside EUSFLAT. For these historical reasons, the society is officially registered in Spain. == Conferences == Starting with 1999, EUSFLAT has been organizing its biannual conferences in odd years. Previous meetings: Palma de Mallorca, Balearic Islands, Spain, September 22–25, 1999 (jointly with National Spanish conference, ESTYLF) Leicester, United Kingdom, September 5–7, 2001 Zittau, Germany, September 10–12, 2003 Barcelona, Catalonia, Spain, September 7–9, 2005 (jointly with 11th Rencontres Francophones sur la Logique Floue et ses Applications) Ostrava, Czech Republic, September 11–14, 2007 Lisbon, Portugal, July 20–24, 2009 (jointly with 13th World Congress of the International Fuzzy Systems Association) Aix-les-Bains, France, July 18–22, 2011 (jointly with Les Rencontres Francophones sur la Logique Floue et ses Applications) Milan, Italy, September 11–13, 2013 Gijón, Spain, June, 30–3 July 2015 == Publications == EUSFLAT publishes the proceedings of its conferences in an open access manner. Until 2010, Mathware & Soft Computing was the official journal of EUSFLAT. On July 1, 2010, the International Journal of Computational Intelligence Systems (Atlantis Press, ISSN 1875-6891 (print) / ISSN 1875-6883 (on-line)) became the official journal of EUSFLAT. EUSFLAT publishes an electronic newsletter with three issues a year. == Presidents == EUSFLAT is led by the President, who is elected for a two-year period, and cannot serve for more than two consecutive periods. Francesc Esteva (1998–2011) Luis Magdalena (2001–2005) Ulrich Bodenhofer (2005–2009) Javier Montero (2009–2013) Gabriella Pasi (2013–present)
Cross-validation (statistics)
Cross-validation, sometimes called rotation estimation or out-of-sample testing, is any of various similar model validation techniques for assessing how the results of a statistical analysis will generalize to an independent data set. Cross-validation includes resampling and sample splitting methods that use different portions of the data to test and train a model on different iterations. It is often used in settings where the goal is prediction, and one wants to estimate how accurately a predictive model will perform in practice. It can also be used to assess the quality of a fitted model and the stability of its parameters. In a prediction problem, a model is usually given a dataset of known data on which training is run (training dataset), and a dataset of unknown data (or first seen data) against which the model is tested (called the validation dataset or testing set). The goal of cross-validation is to test the model's ability to predict new data that was not used in estimating it, in order to flag problems like overfitting or selection bias and to give an insight on how the model will generalize to an independent dataset (i.e., an unknown dataset, for instance from a real problem). One round of cross-validation involves partitioning a sample of data into complementary subsets, performing the analysis on one subset (called the training set), and validating the analysis on the other subset (called the validation set or testing set). To reduce variability, in most methods multiple rounds of cross-validation are performed using different partitions, and the validation results are combined (e.g. averaged) over the rounds to give an estimate of the model's predictive performance. In summary, cross-validation combines (averages) measures of fitness in prediction to derive a more accurate estimate of model prediction performance. == Motivation == Assume a model with one or more unknown parameters, and a data set to which the model can be fit (the training data set). The fitting process optimizes the model parameters to make the model fit the training data as well as possible. If an independent sample of validation data is taken from the same population as the training data, it will generally turn out that the model does not fit the validation data as well as it fits the training data. The size of this difference is likely to be large especially when the size of the training data set is small, or when the number of parameters in the model is large. Cross-validation is a way to estimate the size of this effect. === Example: linear regression === In linear regression, there exist real response values y 1 , … , y n {\textstyle y_{1},\ldots ,y_{n}} , and n p-dimensional vector covariates x1, ..., xn. The components of the vector xi are denoted xi1, ..., xip. If least squares is used to fit a function in the form of a hyperplane ŷ = a + βTx to the data (xi, yi) 1 ≤ i ≤ n, then the fit can be assessed using the mean squared error (MSE). The MSE for given estimated parameter values a and β on the training set (xi, yi) 1 ≤ i ≤ n is defined as: MSE = 1 n ∑ i = 1 n ( y i − y ^ i ) 2 = 1 n ∑ i = 1 n ( y i − a − β T x i ) 2 = 1 n ∑ i = 1 n ( y i − a − β 1 x i 1 − ⋯ − β p x i p ) 2 {\displaystyle {\begin{aligned}{\text{MSE}}&={\frac {1}{n}}\sum _{i=1}^{n}(y_{i}-{\hat {y}}_{i})^{2}={\frac {1}{n}}\sum _{i=1}^{n}(y_{i}-a-{\boldsymbol {\beta }}^{T}\mathbf {x} _{i})^{2}\\&={\frac {1}{n}}\sum _{i=1}^{n}(y_{i}-a-\beta _{1}x_{i1}-\dots -\beta _{p}x_{ip})^{2}\end{aligned}}} If the model is correctly specified, it can be shown under mild assumptions that the expected value of the MSE for the training set is (n − p − 1)/(n + p + 1) < 1 times the expected value of the MSE for the validation set (the expected value is taken over the distribution of training sets). Thus, a fitted model and computed MSE on the training set will result in an optimistically biased assessment of how well the model will fit an independent data set. This biased estimate is called the in-sample estimate of the fit, whereas the cross-validation estimate is an out-of-sample estimate. Since in linear regression it is possible to directly compute the factor (n − p − 1)/(n + p + 1) by which the training MSE underestimates the validation MSE under the assumption that the model specification is valid, cross-validation can be used for checking whether the model has been overfitted, in which case the MSE in the validation set will substantially exceed its anticipated value. (Cross-validation in the context of linear regression is also useful in that it can be used to select an optimally regularized cost function.) === General case === In most other regression procedures (e.g. logistic regression), there is no simple formula to compute the expected out-of-sample fit. Cross-validation is, thus, a generally applicable way to predict the performance of a model on unavailable data using numerical computation in place of theoretical analysis. == Types == Two types of cross-validation can be distinguished: exhaustive and non-exhaustive cross-validation. === Exhaustive cross-validation === Exhaustive cross-validation methods are cross-validation methods which learn and test on all possible ways to divide the original sample into a training and a validation set. ==== Leave-p-out cross-validation ==== Leave-p-out cross-validation (LpO CV) involves using p observations as the validation set and the remaining observations as the training set. This is repeated on all ways to cut the original sample on a validation set of p observations and a training set. LpO cross-validation require training and validating the model C p n {\displaystyle C_{p}^{n}} times, where n is the number of observations in the original sample, and where C p n {\displaystyle C_{p}^{n}} is the binomial coefficient. For p > 1 and for even moderately large n, LpO CV can become computationally infeasible. For example, with n = 100 and p = 30, C 30 100 ≈ 3 × 10 25 . {\displaystyle C_{30}^{100}\approx 3\times 10^{25}.} A variant of LpO cross-validation with p=2 known as leave-pair-out cross-validation has been recommended as a nearly unbiased method for estimating the area under ROC curve of binary classifiers. ==== Leave-one-out cross-validation ==== Leave-one-out cross-validation (LOOCV) is a particular case of leave-p-out cross-validation with p = 1. The process looks similar to jackknife; however, with cross-validation one computes a statistic on the left-out sample(s), while with jackknifing one computes a statistic from the kept samples only. LOO cross-validation requires less computation time than LpO cross-validation because there are only C 1 n = n {\displaystyle C_{1}^{n}=n} passes rather than C p n {\displaystyle C_{p}^{n}} . However, n {\displaystyle n} passes may still require quite a large computation time, in which case other approaches such as k-fold cross validation may be more appropriate. Pseudo-code algorithm: Input: x, {vector of length N with x-values of incoming points} y, {vector of length N with y-values of the expected result} interpolate( x_in, y_in, x_out ), { returns the estimation for point x_out after the model is trained with x_in-y_in pairs} Output: err, {estimate for the prediction error} Steps: err ← 0 for i ← 1, ..., N do // define the cross-validation subsets x_in ← (x[1], ..., x[i − 1], x[i + 1], ..., x[N]) y_in ← (y[1], ..., y[i − 1], y[i + 1], ..., y[N]) x_out ← x[i] y_out ← interpolate(x_in, y_in, x_out) err ← err + (y[i] − y_out)^2 end for err ← err/N === Non-exhaustive cross-validation === Non-exhaustive cross validation methods do not compute all ways of splitting the original sample. These methods are approximations of leave-p-out cross-validation. ==== k-fold cross-validation ==== In k-fold cross-validation, the original sample is randomly partitioned into k equal sized subsamples, often referred to as "folds". Of the k subsamples, a single subsample is retained as the validation data for testing the model, and the remaining k − 1 subsamples are used as training data. The cross-validation process is then repeated k times, with each of the k subsamples used exactly once as the validation data. The k results can then be averaged to produce a single estimation. The advantage of this method over repeated random sub-sampling (see below) is that all observations are used for both training and validation, and each observation is used for validation exactly once. 10-fold cross-validation is commonly used, but in general k remains an unfixed parameter. For example, setting k = 2 results in 2-fold cross-validation. In 2-fold cross-validation, the dataset is randomly shuffled into two sets d0 and d1, so that both sets are equal size (this is usually implemented by shuffling the data array and then splitting it in two). We then train on d0 and validate on d1, followed by training on d1 and validating on d0. When k = n (the number of observations), k-fold cross-validation is equivalent to leave-one-out cr
The Old Axolotl
The Old Axolotl (Polish: Starość aksolotla) is a 2015 digital-only novel by Polish science-fiction author Jacek Dukaj. The novel was released in Polish on March 10, 2015, and shortly afterward, on March 24 that year, in English (translated by Stanley Bill). It has been described as "an experiment in reading (and creating) the electronic literature of the future". It is Dukaj's first novel to be published in English, though several of his short stories (The Golden Galley, 1996, The Iron General, 2010, The Apocrypha of Lem, 2011) have been translated prior to this. The novel has inspired two Netflix original series: the 2020 Belgian Into the Night, and its 2022 Turkish language spin-off Yakamoz S-245. == Plot == The novel presents a post-apocalyptic, cyberpunk vision of Earth where biological life has been wiped out, inhabited by robots and mechs, many of which are humans whose consciousness has been digitized in the wake of an extinction event. == Significance and analysis == The novel is an example of electronic literature, available only in digital formats, and has no traditional paper version. It was designed from the beginning not only to incorporate more traditional elements such as illustrations, but also hypertext, and 3D-printable models of main robotic characters designed by Alex Jaeger, the art director of Transformers films. The novel composition is layered, with the narrative layer, an encyclopedic/hyperlinked footnote layer, and a multimedia layer, including illustrations and a short promotional video by the Oscar-nominated Platige Image studio. One of the novel's central questions is: "What does it mean to be human?" Other subjects include post humanism and other "staples of cyberpunk and related genres, such as the artificial intelligence". The novel is representative of Dukaj's prose, posing philosophical questions about the future of man and technology. The author explained that: "stories such as The Old Axolotl that model an ‘escape from the body’ are born out of a sense of progress as a process of ‘de-animalising’ human beings through science. This has its origin in the pre-Enlightenment intuition of ‘liberation from nature’. For one of the last shackles of nature is corporeality itself, the limitations of our physicality." The other major element of the novel is Dukaj's attempts to introduce the reader to the new style of electronic literature. The novel was nominated for the 2016 Janusz A. Zajdel Award.